International Cancer Research Conference
March 24-26, 2025 | Singapore
Covid and Its Impact on Cancer
The first half of 2020 saw the advent of coronavirus disease 2019 (COVID-19) as a pandemic, which had an immediate and significant impact on cancer care. The COVID-19 pandemic has had a wide-ranging detrimental effect on cancer care, with variable degrees of severity in different places throughout the world. Patients with cancer are a vulnerable population, and they are exposed to a variety of problems during pandemics, including infection susceptibility and disruption of their cancer or regular medical care. Potential cardiovascular complications in cancer patients who have also been infected with SARS-CoV-2 are one of the most pressing concerns for clinicians. The renin-angiotensin-aldosterone system (RAAS) is another area of concern in COVID-19 positive cancer patients.
- RAAS
- Cardiovascular complications
- Key biomarkers in COVID-19 cancer patients
- Oncology Consultation and Care During and Post-COVID-19
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Jianhua Luo
University of Pittsburgh, United States
Kaushala Prasad Mishra
Asian Association for Radiation Research (AARR), India
Mariola Wioletta Borowska
Maria Sklodowska-Curie National Research Institute of Oncology, Poland
Ibrahim El Bayoumy
Tanta faculty of medicine, Kuwait
Andrea González Báez
Autonomous University of Nuevo Leon, MexicoSubmit your abstract Today
Title :
Pietro Salvatori, Private Practice, Italy
Title :
Jianhua Luo, University of Pittsburgh, United States
Title :
Marika Crohns, Sanofi, Germany
Title : RNA binding proteins in the pathogenesis of pediatric cancer
Atif A Ahmed, University of Washington-Seattle Children’s Hospital, United States
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom